| 摘要 |
A method for predicting cardiovascular risk in the patients with systemic lupus erythematosis and concomitant antiphospholipid syndrome comprises the assessment of ESR (erythrocyte sedimentation rate), thrombocytopenia, leukocytosis, detection of anticardiolipin antibodies and lupous anticoagulant, Wassermann's test, detection of antinuclear factor, anti-DNA antibodies, T and B lymphocytes, IgG antibodies against beta-2-glicoprotein-1. C-reactive protein is assayed in blood serum. When the level of C-reactive protein exceeds 8.2 mg/L, the risk of cardiovascular pathology is stated. |
